Accelerator Corporation, a privately held, venture-capital-backed biotechnology investment and development company, announced today the Series A financing of Oncofactor Corporation. This is the twelfth company backed by Accelerator and its first investment based on internal intellectual property developed at Accelerator. Oncofactor is developing cancer therapeutics that disrupt signaling pathways between tumors and the immune system. The investors participating in the Series A investment in Oncofactor include Accelerator syndicate partners: Alexandria Real Estate Equities; Amgen Ventures; ARCH Venture Partners, Inc.; OVP Venture Partners; PPD, Inc.; and WRF Capital.
